ArticleClinical and experimental vaccine research2025
Impact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients.
Article in Clinical and experimental vaccine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of COVID-19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study.Neurourology and urodynamics · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Benign prostatic hyperplasia (BPH) is a common condition in men that can impact quality of life, especially in older age. BPH is nonmalignant prostate enlargement associated with lower urinary tract symptoms (LUTS). Various factors like aging, hormonal imbalance, and inflammation contribute to BPH, with androgen dysregulation playing a key role. The coronavirus disease 2019 (COVID-19) pandemic raised concerns about vaccine side effects, particularly in BPH patients experiencing LUTS. Research is ongoing to understand the impact of COVID-19 vaccination on LUTS in BPH patients. Materials and Methods: This prospective longitudinal study conducted at Sina Hospital in Tehran, Iran, from September 2022 to March 2023 enrolled 106 BPH patients receiving COVID-19 vaccines. Ultrasonography, total and free prostate specific antigen (PSA) test, and urine analysis were performed, and International Prostate Symptom Score questionnaires were completed before the vaccination. Vaccines included Oxford University/AstraZeneca, Sinopharm, or Sputnik-V, with booster doses administered per manufacturer protocol. Three months post-booster shot, patients were re-evaluated with the same questionnaire. Data was analyzed using SPSS software. Results: Out of 3,591 individuals receiving COVID-19 vaccine, 106 were eligible for analysis. The mean ± standard deviation age on vaccination day was 65.4±11.74 years. Individuals receiving COVID-19 vaccines found no significant changes in PSA levels or prostate volume post-vaccination. Among urinary symptoms, urgency, dysuria, frequency, and hematuria rates increased significantly (p-value<0.05). Other symptoms showed no statistical differences. Conclusion: Our findings elucidate that urgency, dysuria, frequency, and hematuria may be exacerbated after COVID-19 vaccination in BPH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.